| pubmed-article:21716849 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21716849 | lifeskim:mentions | umls-concept:C0006142 | lld:lifeskim |
| pubmed-article:21716849 | lifeskim:mentions | umls-concept:C0205160 | lld:lifeskim |
| pubmed-article:21716849 | lifeskim:mentions | umls-concept:C1414313 | lld:lifeskim |
| pubmed-article:21716849 | lifeskim:mentions | umls-concept:C0205174 | lld:lifeskim |
| pubmed-article:21716849 | lifeskim:mentions | umls-concept:C0599894 | lld:lifeskim |
| pubmed-article:21716849 | pubmed:dateCreated | 2011-6-30 | lld:pubmed |
| pubmed-article:21716849 | pubmed:abstractText | Our preliminary data show that erlotinib inhibits Triple-negative breast cancer (TNBC) in a xenograft model. However, inhibition of metastasis by erlotinib is accompanied by nonspecific effects because erlotinib can inhibit other kinases; thus, more direct targets that regulate TNBC metastasis need to be identified to improve its therapeutic efficacy. | lld:pubmed |
| pubmed-article:21716849 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21716849 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21716849 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21716849 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21716849 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21716849 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21716849 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21716849 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21716849 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21716849 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21716849 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21716849 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21716849 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21716849 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21716849 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21716849 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21716849 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21716849 | pubmed:status | PubMed-not-MEDLINE | lld:pubmed |
| pubmed-article:21716849 | pubmed:issn | 1837-9664 | lld:pubmed |
| pubmed-article:21716849 | pubmed:author | pubmed-author:UenoNaoto TNT | lld:pubmed |
| pubmed-article:21716849 | pubmed:author | pubmed-author:ZhangDongweiD | lld:pubmed |
| pubmed-article:21716849 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21716849 | pubmed:volume | 2 | lld:pubmed |
| pubmed-article:21716849 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21716849 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21716849 | pubmed:pagination | 324-8 | lld:pubmed |
| pubmed-article:21716849 | pubmed:dateRevised | 2011-8-1 | lld:pubmed |
| pubmed-article:21716849 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21716849 | pubmed:articleTitle | Targeting EGFR in Triple Negative Breast Cancer. | lld:pubmed |
| pubmed-article:21716849 | pubmed:affiliation | 1. Breast Cancer Translational Research Laboratory, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; | lld:pubmed |
| pubmed-article:21716849 | pubmed:publicationType | Journal Article | lld:pubmed |
